Evgen is a UK-based biopharmaceutical company that is taking a novel approach to developing a new anti-cancer drug. Evgen’s lead compound is a pharmaceutical drug called Sulforadex® that retards tumour growth and is a potent anticancer stem cell agent – making it a very attractive asset for big pharma or biotech going forward.

In 2014, the management team at Evgen were preparing the company for an Initial Public Offering (IPO) on AIM (the Alternative Investment Market) and were looking to re-position the brand and refresh its visual identity.